Plan de Negocios para la creacion de una EBT en el PTLC.

IGNACIO RINTOUL

2010-12-01/2011-08-01

1-16

Química

Produccion animal

Executive abstract NOVARTEK is a young company devoted to the development of technological solutions and products based on materials and chemistry engineering. The company was created in 2011 in the frame of the Bolsa de Comercio de Santa Fe Award and it is located at the Parque Tecnológico Litoral Centro. NOVARTEK has a flexible and dynamic organization designed to be functional to business and clients. The business units linepipe presents stages from concept demonstration to prototyping and pilot plant. Our most advanced business unit is controlled drug delivery systems and platforms for veterinary applications. The most valuable competitive advantage of NOVARTEK is the knowledge to develop hightech global business with local resources. Our projects have been evaluated and have received the support of several recognized institutions for science, technology and business warranting the excellent intellectual quality of our ideas. Our goals for the next two years are the transfer of our business units from prototypes and pilot plant to industrial scale and commerciallization. For testing market and essay of penetration, we plan to produce near 30.000 doses of microcapsules for a net 150.000USD annually. In addition, we will move from the in-vitro to in-vivo the development of drug delivery systems. Our needs are diverse and depend on each particular business unit. Statistically, each business units requires an average investment about 400.000 AR$ to move from the concept demonstration to prototyping and pilot plant stage.ógico Litoral Centro. NOVARTEK has a flexible and dynamic organization designed to be functional to business and clients. The business units linepipe presents stages from concept demonstration to prototyping and pilot plant. Our most advanced business unit is controlled drug delivery systems and platforms for veterinary applications. The most valuable competitive advantage of NOVARTEK is the knowledge to develop hightech global business with local resources. Our projects have been evaluated and have received the support of several recognized institutions for science, technology and business warranting the excellent intellectual quality of our ideas. Our goals for the next two years are the transfer of our business units from prototypes and pilot plant to industrial scale and commerciallization. For testing market and essay of penetration, we plan to produce near 30.000 doses of microcapsules for a net 150.000USD annually. In addition, we will move from the in-vitro to in-vivo the development of drug delivery systems. Our needs are diverse and depend on each particular business unit. Statistically, each business units requires an average investment about 400.000 AR$ to move from the concept demonstration to prototyping and pilot plant stage.